These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21438824)

  • 1. The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dong.
    Rosenblum M; McLaughlin P
    Leuk Lymphoma; 2011 Apr; 52(4):550-1. PubMed ID: 21438824
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins.
    Frankel AE; FitzGerald D; Siegall C; Press OW
    Cancer Res; 1996 Feb; 56(4):926-32. PubMed ID: 8631036
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
    Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
    Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I immunotoxin trial in patients with B-cell lymphoma.
    Vitetta ES; Stone M; Amlot P; Fay J; May R; Till M; Newman J; Clark P; Collins R; Cunningham D
    Cancer Res; 1991 Aug; 51(15):4052-8. PubMed ID: 1855219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
    Wenning LA; Murphy RM
    Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
    Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
    Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
    Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
    Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins: the power and the glory.
    Wawrzynczak EJ; Derbyshire EJ
    Immunol Today; 1992 Oct; 13(10):381-3. PubMed ID: 1418372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
    Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
    Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
    J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in the treatment of human B-cell malignancies.
    Link BK; Weiner GJ
    Leuk Lymphoma; 1998 Oct; 31(3-4):237-49. PubMed ID: 9869188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.